[go: up one dir, main page]

AU2000279624A1 - Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient - Google Patents

Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient

Info

Publication number
AU2000279624A1
AU2000279624A1 AU2000279624A AU7962400A AU2000279624A1 AU 2000279624 A1 AU2000279624 A1 AU 2000279624A1 AU 2000279624 A AU2000279624 A AU 2000279624A AU 7962400 A AU7962400 A AU 7962400A AU 2000279624 A1 AU2000279624 A1 AU 2000279624A1
Authority
AU
Australia
Prior art keywords
blooe
antagonist
active ingredient
agent containing
lowering agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2000279624A
Inventor
Norihiro Nishimoto
Kazuyuki Yoshizaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of AU2000279624A1 publication Critical patent/AU2000279624A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2000279624A 2000-10-27 2000-10-27 Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient Abandoned AU2000279624A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2000/007603 WO2002036164A1 (en) 2000-10-27 2000-10-27 Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient

Publications (1)

Publication Number Publication Date
AU2000279624A1 true AU2000279624A1 (en) 2002-05-15

Family

ID=11736635

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2000279624A Abandoned AU2000279624A1 (en) 2000-10-27 2000-10-27 Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient

Country Status (3)

Country Link
US (1) US8173126B2 (en)
AU (1) AU2000279624A1 (en)
WO (1) WO2002036164A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998042377A1 (en) 1997-03-21 1998-10-01 Chugai Seiyaku Kabushiki Kaisha Preventives or remedies for sensitized t cell-related diseases containing il-6 antagonists as the active ingredient
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
EP3269738A1 (en) 2004-03-24 2018-01-17 Chugai Seiyaku Kabushiki Kaisha Subtypes of humanized antibody against interleukin-6 receptor
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
TWI501976B (en) * 2007-05-21 2015-10-01 Alder Biopharmaceuticals Inc Antibodies to tnf alpha and use thereof
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
CA2688146C (en) 2007-05-21 2018-03-06 Alder Biopharmaceuticals, Inc. Antibodies to il-6 and use thereof
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
PE20091174A1 (en) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT
US8034344B2 (en) 2008-05-13 2011-10-11 Novimmune S.A. Anti-IL-6/IL-6R antibodies and methods of use thereof
US8323649B2 (en) * 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
WO2011066371A2 (en) 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antibodies to il-6 and use thereof
DK2493922T3 (en) 2009-10-26 2017-04-24 Hoffmann La Roche Process for preparing a glycosylated immunoglobulin
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
JP2013523185A (en) * 2010-04-13 2013-06-17 ワイゼンタル， ラリー マーク Method for detecting massive calcium accumulation death in endothelial cells
EP3351559A3 (en) 2010-11-08 2018-10-31 F. Hoffmann-La Roche AG Subcutaneously administered anti-il-6 receptor antibody
DK2643018T3 (en) 2010-11-23 2021-01-18 Vitaeris Inc ANTI-IL-6 ANTIBODIES FOR THE TREATMENT OF ORAL MUCOSITIS
JO3370B1 (en) 2011-11-10 2019-03-13 Regeneron Pharma Methods of inhibiting tumor growth by antagonizing il-6 receptor
CA2913687C (en) 2013-07-04 2022-12-13 F. Hoffmann-La Roche Ag Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples
WO2017147169A1 (en) 2016-02-22 2017-08-31 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin a analogues or metabolites, and estradiol metabolites
TWI850514B (en) 2017-02-01 2024-08-01 耶魯大學 Precision treatment of heart failure and cardiorenal syndrome
US11033496B2 (en) 2017-03-17 2021-06-15 The Regents Of The University Of Michigan Nanoparticles for delivery of chemopreventive agents
MX2020006882A (en) 2018-01-05 2020-09-07 Novo Nordisk As METHODS TO TREAT INFLAMMATION MEDIATED BY INTERLEUKIN-6 WITHOUT IMMUNOSUPPRESSION.
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU668349B2 (en) * 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
JPH05148156A (en) * 1991-11-28 1993-06-15 Toray Ind Inc Proliferating agent for vascular endothelical cell
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
WO1998042377A1 (en) * 1997-03-21 1998-10-01 Chugai Seiyaku Kabushiki Kaisha Preventives or remedies for sensitized t cell-related diseases containing il-6 antagonists as the active ingredient

Also Published As

Publication number Publication date
WO2002036164A1 (en) 2002-05-10
US20070243189A1 (en) 2007-10-18
US8173126B2 (en) 2012-05-08

Similar Documents

Publication Publication Date Title
AU2000279624A1 (en) Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient
AU2000279625A1 (en) Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient
AU2002210952A1 (en) Preventives or remedies for psoriasis containing as the active ingredient IL-6 antagonist
IL161940A0 (en) Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient
IL157741A0 (en) Pharmaceutical compositions containing an antihyperplastic active agent
AU2001290250A1 (en) Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
AU2002324624A1 (en) Sequestered antagonist formulations
EP1461044A4 (en) Pharmaceutical compositions comprising active vitamin d compounds
NO20003196L (en) Immediately dissolving dosage formulation
IL229510A0 (en) Dosage form containing pantoprazole as active ingredient
AU2002302544A1 (en) Active ingredient combinations for hair-dyeing agents
IL159345A0 (en) Active ingredient combination for pharmacological addictive substances or intoxicant therapy
AU2001272383A1 (en) Fungicidal combinations of active agents
HUP0303636A3 (en) Dihydronaphthalenederivative compounds and pharmaceutical compositions containing them as active ingredient
AU2002340573A8 (en) Powdery active ingredient formulations
GB0107751D0 (en) Pharmaceutically active compounds
GB0106631D0 (en) Pharmaceutically active compounds
IL154258A0 (en) Fungicidal formulation
AU2003259532A1 (en) Ready-to-drink formulation containing an active ingredient
AU2001292276A1 (en) Nitrogen-containing compounds and ccr3 inhibitors containing the same as the active ingredient
AU2003252660A1 (en) Tocolytic agent comprising ep2 agonist as the active ingredient
PL368613A1 (en) Pharmaceutical formulation containing an ltb4 antagonist
AU2002238875A1 (en) Remedies for depression containing ep1 antagonist as the active ingredient
AU2001292258A1 (en) Remedies for hepatic diseases containing calcium channel antagonist as the active ingredient
AU2002355890A1 (en) Active ingredient mixtures